Azithromycin-Prevention in Labor Use Study (A-PLUS)

Phase 3

Completed

Conditions: Neonatal SEPSIS
Postpartum Sepsis
Maternal Infections Affecting Fetus or Newborn
Maternal Sepsis During Labor
Maternal Death
Neonatal Death

Interventions: Drug: Placebo
Drug: Azithromycin

Registration Number: NCT03871491

Lead Sponsor: NICHD Global Network for Women's and Children's Health

Brief Summary: Maternal and neonatal infections are among the most frequent causes of maternal and neonatal deaths, and current antibiotic strategies have not been effective in preventing many of these deaths. Recently, a randomized clinical trial conducted in a single site in The Gambia showed that treatment with oral dose of 2 g azithromycin vs. placebo for all women in labor reduced selected maternal and neonatal infections. However, it is unknown if this therapy reduces maternal and neonatal sepsis and mortality. The A-PLUS trial includes two primary hypotheses, a maternal hypothesis and a neonatal hypothesis. First, a single, prophylactic intrapartum oral dose of 2 g azithromycin given to women in labor will reduce maternal death or sepsis. Second, a single, prophylactic intrapartum oral dose of 2 g azithromycin given to women in labor will reduce intrapartum/neonatal death or sepsis.

Detailed Description: The A-PLUS Trial is a randomized, placebo-controlled, parallel multicenter clinical trial. The study intervention is a single, prophylactic intrapartum oral dose of 2 g azithromycin, with a comparison with a single intrapartum oral dose of an identical appearing placebo. For the A-PLUS randomized control trial (RCT), a total of 34,000 laboring women from eight research sites in sub-Saharan Africa, South Asia, and Latin America will be randomized with one-to-one ratio to intervention/placebo. In response to the global coronavirus pandemic, research sites will also collect data on COVID-19 signs/symptoms, diagnosis, and treatment in order to estimate the incidence of infection and evaluate the impact of the pandemic on the target population.

Prior to the initiation of the A-PLUS RCT, research sites will conduct an observational pilot study using the RCT's planned infrastructure in order to characterize the current practices at participating research facilities and optimize the identification of suspected infection for the RCT. The information obtained in the pilot study will be used to validate estimates of intrapartum deaths, maternal sepsis, and neonatal sepsis used in the sample size calculations for the RCT. Finally, the pilot study will allow the research sites to inventory and upgrade local capacity to conduct routine cultures during the RCT.

A maximum of 16,000 women, separate from the sample for the main trial, will be enrolled in the pilot, across all eight research sites, with no more than 2000 women enrolled at any individual site. Research sites will be eligible to transition to the RCT when a minimum of 600 participants have been enrolled in the pilot study with evidence of (a) high rates of follow-up; (2) acceptable data quality and completeness; and (3) there are no concerns about identification and reporting of infection.

Given the clinical benefits of intrapartum azithromycin so far reported in two trials and the likelihood that it may become the usual practice if the investigator's large RCT confirms the reported benefits, it is important to monitor antibiotic resistance to determine the safety of azithromycin prophylaxis. Therefore, the RCT will also include an ancillary study (referred to as the antimicrobial resistance (AMR) sub-study) to monitor antimicrobial resistance and maternal and newborn microbiome effects of the single dose of prophylactic azithromycin using the following methodology

1. For all mothers enrolled in the RCT and their infants:

a. Routine clinical monitoring at baseline and three post-partum time points (3 days, 7 days, and 42 days), with culture and sensitivity testing in cases of suspected bacterial infections;

2. Among a subset of 1000 randomly selected maternal-infant dyads:

1. Serial susceptibility monitoring of antimicrobial resistance patterns (including azithromycin resistance) from selected maternal and newborn flora through culture and sensitivity testing. Serial monitoring will be conducted at baseline and three post-partum time points (1 week, 6 weeks, and 3 months).

2. Serial microbiome collection and storage of specimens for future testing to monitor maternal and newborn microbiome status of selected sites.

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 58747

Inclusion Criteria

Pregnant women in labor ≥28 weeks Gestational Age (GA) (by best estimate) with a pregnancy with one or more live fetuses who plan to deliver vaginally in a facility.
Admitted to health facility with clear plan for spontaneous or induced delivery.
Live fetus must be confirmed via a fetal heart rate by Doptone prior to randomization.
≥18 years of age or minors 14-17 years of age in countries where married or pregnant minors (or their authorized representatives) are legally permitted to give consent.
Have provided written informed consent.
Pregnant women in labor ≥28 weeks GA (by best estimate) with a pregnancy with one or more live fetuses who plan to deliver vaginally in a facility.
Admitted to health facility with clear plan for spontaneous or induced delivery.
Live fetus must be confirmed via presence of a fetal heart rate prior to randomization.
≥18 years of age or minors 14-17 years of age in countries where married or pregnant minors (or their authorized representatives) are legally permitted to give consent.
Have provided written informed consent [Note: written informed consent may be obtained during antenatal care, but verbal re-confirmation may be needed (per local regulations) at the time of randomization].

Exclusion Criteria

Non-emancipated minors (as per local regulations)
Evidence of chorioamnionitis or other infection requiring antibiotic therapy at time of eligibility (however, women given single prophylactic antibiotics with no plans to continue after delivery should not be excluded).
Arrhythmia or known history of cardiomyopathy.
Allergy to azithromycin or other macrolides that is self-reported or documented in the medical record.
Any use of azithromycin, erythromycin, or other macrolide in the 3 days or less prior to randomization.
Plan for cesarean delivery prior to randomization.
Preterm labor undergoing management with no immediate plan to proceed to delivery.
Advanced stage of labor (>6 cm or 10 cm cervical dilation per local standards) and pushing or too distressed to understand, confirm, or give informed consent regardless of cervical dilation.
Are not capable of giving consent due to other health problems such as obstetric emergencies (for example, antepartum hemorrhage) or mental disorder.
Any other medical conditions that may be considered a contraindication per the judgment of the site investigator.
Previous randomization in the trial.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	By random allocation, participants will receive four oral placebo pills containing a non-antimicrobial agent directly after randomization.
Intervention	Azithromycin	The study intervention is a single 2 g dose of directly observed oral azithromycin.

Primary Outcome Measures

Name	Time	Method
Maternal Death or Sepsis Within 6 Weeks (42 Days) Post-delivery in Intervention vs. Placebo Group.	Within 6 weeks (42 days)	Maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.
Intrapartum/Neonatal Death or Sepsis Within 4 Weeks (28 Days) Post-delivery in Intervention vs. Placebo Group	Within 4 weeks (28 days) post-delivery	Intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group. This outcome is measured among stillbirths and neonates with 28-day status available born to women randomized. The study includes multiple births so there are more stillbirths and neonates than participants enrolled.

Secondary Outcome Measures

Name	Time	Method
Maternal Sepsis	Within 42 days post-delivery	Maternal sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.
Maternal Death Due to Sepsis	Within 42 days post-delivery	Maternal death due to sepsis using the Global Network algorithm for cause of death
Chorioamnionitis	Between date/time of randomization and date/time of delivery (up to 120 hours before delivery)	Fever (\>100.4°F/38°C) in addition to one or more of the following: fetal tachycardia ≥160 bpm, maternal tachycardia \>100 bpm, tender uterus between contractions, or purulent/foul smelling discharge from uterus prior to delivery.
Endometritis	Within 42 days post-delivery	Fever (\>100.4°F/38°C) in addition to one or more of maternal tachycardia \>100 bpm, tender uterine fundus, or purulent/foul smelling discharge from uterus after delivery.
Cesarean Wound Infection	Within 42 days post-delivery	Wound infection (Purulent infection of a Cesarean wound with or without fever. In the absence of purulence, requires presence of fever \>100.4°F/38°C and at least one of the following signs of local infection: pain or tenderness, swelling, heat, or redness around the incision/laceration);
Perineal Wound Infection	Within 42 days post-delivery	Wound infection (Purulent infection of a perineal wound with or without fever. In the absence of purulence, requires presence of fever \>100.4°F/38°C and at least one of the following signs of local infection: pain or tenderness, swelling, heat, or redness around the incision/laceration);
Other Infections	Within 42 days post-delivery	Abdominopelvic abscess (Evidence of pus in the abdomen or pelvis noted during open surgery, interventional aspiration or imaging); Pneumonia (Fever \>100.4°F/38°C and clinical symptoms suggestive of lung infection including cough and/or tachypnea \>24 breaths/min or radiological confirmation); Pyelonephritis (Fever \>100.4°F/38°C and one or more of the following: urinalysis/dip suggestive of infection, costovertebral angle tenderness, or confirmatory urine culture); Mastitis/breast abscess or infection (Fever \>100.4°F/38°C and one or more of the following: breast pain, swelling, warmth, redness, or purulent drainage). Other bacterial infection.
Use of Subsequent Maternal Antibiotic Therapy	After randomization to 42 days post-delivery. Randomization occurs between labor onset and delivery (0 to 120 hours before delivery). 42 participants were randomized >120 hours before delivery due to false labor.	Use of subsequent maternal antibiotic therapy after randomization to 42 days postpartum for any reason.
Maternal Initial Hospital Length of Stay	Time from drug administration (which occurs between onset of labor and delivery) and discharge from delivery hospital (0 to 45 days)	Time from drug administration until initial discharge after delivery (time may vary by site).
Maternal Readmissions	After delivery discharge and within 42 days post-delivery	Maternal readmissions after delivery discharge and within 42 days of delivery
Maternal Admission to Special Care Units	Within 42 days post-delivery (reported during study)	Maternal admission to special care units
Maternal Unscheduled Visit for Care	Within 42 days post-delivery (reported during study)	Maternal unscheduled visit for care
Maternal GI Symptoms	Within 42 days post-delivery (reported during study)	Maternal GI symptoms including nausea, vomiting, and diarrhea and other reported side effects.
Neonatal Sepsis	Within 28 days post-delivery	Neonatal sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group. This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.
Neonatal Death Due to Sepsis	Within 28 days post-delivery	Neonatal death due to sepsis using the Global Network algorithm for causes of death. This outcome is measured among neonates with 28-day status available born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.
Other Neonatal Infections	Within 28 days post-delivery	Other neonatal infections (e.g. eye infection, skin infection). This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.
Neonatal Initial Hospital Length of Stay	Time from delivery to discharge from delivery hospital (0 to 62 days)	Neonatal initial hospital length of stay, defined as time of delivery until initial discharge (time may vary by site). This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.
Neonatal Readmissions	After delivery discharge and within 42 days of delivery	Neonatal readmissions to facility after delivery discharge and within 42 days of delivery. This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.
Neonatal Admission to Special Care Units	Within 42 days post-delivery (reported during study)	Neonatal admission to special care units. This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.
Neonatal Unscheduled Visit for Care	Within 42 days post-delivery (reported during study)	Neonatal unscheduled visit for care. This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.
Pyloric Stenosis Within 42 Days of Delivery	Within 42 days post-delivery	Pyloric stenosis within 42 days of delivery, defined as clinical suspicion based on severe vomiting leading to death, surgical intervention (pyloromyotomy) as verified from medical records, or radiological confirmation. This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.

Trial Locations

Locations (8): Kinshasa School of Public Health
🇨🇩
Kinshasa, Congo, The Democratic Republic of the
ICDDRB
🇧🇩
Dhaka, Bangladesh
Institute for Nutrition of Central America and Panama (INCAP)
🇬🇹
Guatemala City, Guatemala
Jawaharlal Nehru Medical College
🇮🇳
Belagam, India
University Teaching Hospital
🇿🇲
Lusaka, Zambia
Moi University School of Medicine
🇰🇪
Eldoret, Kenya
Lata Medical Research Foundation
🇮🇳
Nagpur, India
The Aga Khan University
🇵🇰
Karachi, Pakistan